NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma

This trial tests a drug called poseltinib (NB02) — a targeted oral therapy that blocks a protein called BTK — in people with certain types of slow-growing lymphoma (a blood cancer) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 19–80 years old - You have been diagnosed with follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma - Your lymphoma has relapsed or stopped responding to at least 2 prior treatment regimens - You are reasonably functional (ECOG score 0–2) **You may NOT be eligible if...** - You have previously been treated with poseltinib or another BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib) and your disease progressed on it - You cannot swallow oral medication - You have active HIV, hepatitis B, or hepatitis C - You were enrolled in another clinical trial within the past 4 weeks Talk to your doctor to see if this trial is right for you.